Inside Telix: The Aussie guided nuclear missile for cancer

Radio-pharma biotech Telix is building on the success – and the cashflow – from its nuclear-guided prostate cancer tool to aim for new cancers, and new treatments.

Christian Behrenbruch was outraged. That’s what started it all. The then 26-year-old PhD candidate from Melbourne was at a routine lab meeting at Oxford when it was mentioned that the lab was dropping a bunch of patents it owned. 

He couldn’t get his head around it. “We’d developed these amazing technologies that would allow the early diagnosis of breast cancer, and nobody was interested: not the medical imaging companies nor the med-tech companies. I found that deeply offensive.”